What type of study is this?

This is a Cohort Study study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

To evaluate the efficacy and safety of bortezomib-bendamustine-melphalan versus high-dose melphalan in relapsed multiple myeloma.

December 8, 2025Blood

Bortezomib-bendamustine-melphalan or high-dose melphalan in autologous hematopoietic stem cell transplantation for previously transplanted relapsed multiple myeloma – a single center retrospective cohort study

View Full Paper

Ask AI

Bookmark

Authors

ESEmma SmittGävle Hospital

Discussion

Member takes

Implication

Retrospective cohort study finds conditioning regimen with bendamustine and melphalan improves progression-free survival in relapsed multiple myeloma.

Key Points

To evaluate the efficacy and safety of bortezomib-bendamustine-melphalan versus high-dose melphalan in relapsed multiple myeloma.
Retrospective cohort study of patients undergoing autologous hematopoietic stem cell transplantation
Comparison of BBM regimen with HDM in two different cohorts
Assessment of time to next treatment, progression-free survival, and overall survival
Median time to next treatment was 28.9 months for BBM versus 32.1 months for HDM
Progression-free survival favored BBM with 21.6 months compared to 25.0 months for HDM
No significant difference in adverse events, but trends noted for higher febrile neutropenia in BBM cohort

Cite This Study

Emma Smitt (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de34 https://doi.org/10.1182/blood-2025-5811

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study finds conditioning regimen with bendamustine and melphalan improves progression-free survival in relapsed multiple myeloma.

Bortezomib-bendamustine-melphalan or high-dose melphalan in autologous hematopoietic stem cell transplantation for previously transplanted relapsed multiple myeloma – a single center retrospective cohort study

Discussion

Member takes

Implication

Key Points

Cite This Study

Bortezomib-bendamustine-melphalan or high-dose melphalan in autologous hematopoietic stem cell transplantation for previously transplanted relapsed multiple myeloma – a single center retrospective cohort study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider